Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antipsychotics
Biotech
BMS' schizophrenia drug shows long-term benefit with new data
The crown jewel of BMS' $14 billion Karuna acquisition was schizophrenia drug KarXT, but five additional assets are awaiting further assessment.
Max Bayer
Apr 6, 2024 1:15pm
Karuna's new schizophrenia drug reaches FDA's desk
Sep 28, 2023 11:12am
Autoreceptor absence fuels dopamine dysfunction in schizophrenia
Nov 1, 2022 11:00am